Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Evofosfamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunoGenesis Announces Publication of Phase 1 Data in Advanced Cancer
    ImmunoGenesis Announces Publication of Phase 1 Data in Advanced Cancer

    16 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/immunogenesis-announces-publication-of-phase-1-data-on-its-hypoxia-reversal-agent-highlighting-efficacy-and-genetic-expression-correlatives-in-advanced-cancer-301313485.html

    PRNEWSWIRE
    16 Jun 2021
    Share Share
    Shares in Molecular Templates surge after announcement of Takeda collaboration
    Shares in Molecular Templates surge after announcement of Takeda collaboration

    20 Sep 2018

    // Louis Goss PHARMA FILE

    http://www.pharmafile.com/news/518821/shares-molecular-templates-surge-after-announcement-takeda-collaboration

    Louis Goss PHARMA FILE
    20 Sep 2018
    Share Share
    Molecular Templates and Takeda Deal Worth up to $632 Million
    Molecular Templates and Takeda Deal Worth up to $632 Million

    20 Sep 2018

    // Alex Keown BIOSPACE

    https://www.biospace.com/article/am6a-molecular-templates-and-takeda-to-take-on-multiple-myeloma-in-deal-worth-up-to-632-million/

    Alex Keown BIOSPACE
    20 Sep 2018
    Share Share